Dose Per Body Weight Predicts Incidence and Severity of Apalutamide-Related Skin Rash in Metastatic Castration-Sensitive Prostate Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Apalutamide (APA) dose per body weight may predict skin rash incidence in prostate cancer patients. Higher doses (≥3.33 mg/kg) correlated with increased rash severity, but not progression-free survival.
Area Of Science
- Oncology
- Pharmacology
- Dermatology
Background
- Apalutamide (APA) improves survival in metastatic castration-sensitive prostate cancer (mCSPC).
- Japanese patients exhibit higher rates of APA-induced skin rash compared to global populations.
- The study explored APA dosage relative to body weight as a predictor for skin rash.
Purpose Of The Study
- To investigate the predictive value of apalutamide (APA) dose per body weight for skin rash incidence in mCSPC patients.
- To identify an optimal APA cutoff dose associated with skin rash occurrence.
- To assess the impact of APA dosage on skin rash severity and progression-free survival (PFS).
Main Methods
- Retrospective review of 128 mCSPC patients treated with APA (Jan 2018-Dec 2022).
- Receiver operating characteristic (ROC) analysis to determine the optimal APA cutoff dose (mg/kg).
- Comparison of skin rash incidence, severity, and PFS after propensity score matching.
Main Results
- An optimal cutoff dose of 3.33 mg/kg was identified for predicting skin rash.
- Patients receiving ≥3.33 mg/kg had significantly higher incidence of ≥G3 skin rash (19.7% vs. 6.5%, P = .037).
- The cutoff dose stratified time to rash occurrence and discontinuation due to rash (P = .005, P = .009), but did not impact PFS.
Conclusions
- Drug dosage per body weight may predict the incidence and severity of apalutamide-induced skin rash.
- A dose of 3.33 mg/kg appears to be a critical threshold for increased rash risk.
- Further large-scale prospective studies are warranted to validate these findings and optimize dosage recommendations.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
